SARS-CoV-2 RNA quantification using droplet digital RT-PCR

Natalie N. Kinloch^{1,2}, Gordon Ritchie^{3,4}, Winnie Dong², Kyle D. Cobarrubias², Hanwei Sudderuddin², Tanya Lawson³, Nancy Matic^{3,4}, Julio S.G. Montaner^{2,5}, Victor Leung^{3,4,5}, Marc G. Romney^{3,4}, Christopher F. Lowe^{3,4}, Chanson J. Brumme^{2,5#}, Zabrina L. Brumme^{1,2#}

#denotes equal contribution

¹Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada

²British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

³Division of Medical Microbiology and Virology, St Paul's Hospital, Vancouver, British Columbia, Canada

⁴Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

⁵Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Running Title: SARS-CoV-2 RNA quantification using RT-ddPCR

Keywords: SARS-CoV-2; RT-ddPCR; ddPCR; viral load; quantification; COVID-19

Correspondent Footnote:

Zabrina L. Brumme, Ph.D.
Professor, Faculty of Health Sciences
Simon Fraser University
8888 University Drive
Burnaby, BC, Canada
V5A 1S6
778-782-8872
zbrumme@sfu.ca

Chanson J. Brumme, Ph.D.
Assistant Professor, Faculty of Medicine
University of British Columbia
675-1081 Burrard Street, St. Paul's Hospital
Vancouver, BC
V6Z 1Y6
604-682-2344 ext. 63211
cbrumme@bccfe.ca

Abstract

Quantitative viral load assays have transformed our understanding of – and ability to manage – viral diseases. They hold similar potential to advance COVID-19 control and prevention, but SARS-CoV-2 viral load tests are not yet widely available. SARS-CoV-2 molecular diagnostic tests, which typically employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR), yield semi-quantitative results only. Reverse transcriptase droplet digital PCR (RT-ddPCR), a technology that partitions each reaction into 20,000 nanolitre-sized droplets prior to amplification, offers an attractive platform for SARS-CoV-2 RNA quantification. We evaluated eight primer/probe sets originally developed for real-time RT-PCR-based SARS-CoV-2 diagnostic tests for use in RT-ddPCR, and identified three (Charité-Berlin E-Sarbeco and Pasteur Institute IP2 and IP4) as the most efficient, precise and sensitive for RT-ddPCR-based SARS-CoV-2 RNA quantification. Analytical efficiency of the E-Sarbeco primer/probe set, for example, was ~83%, while assay precision, as measured by the coefficient of variation, was ~2% at 1000 input copies/reaction. Lower limits of quantification and detection for this primer/probe set were 18.6 and 4.4 input SARS-CoV-2 RNA copies/reaction, respectively. SARS-CoV-2 RNA viral loads in a convenience panel of 48 COVID-19-positive diagnostic specimens spanned a $6.2\log_{10}$ range, confirming substantial viral load variation *in vivo*. We further calibrated RT-ddPCR-derived SARS-CoV-2 E gene copy numbers against cycle threshold (C_t) values from a commercial real-time RT-PCR diagnostic platform. The resulting log-linear relationship can be used to mathematically derive SARS-CoV-2 RNA copy numbers from C_t values, allowing the wealth of available diagnostic test data to be harnessed to address foundational questions in SARS-CoV-2 biology.

Introduction

Quantitative viral load assays have revolutionized our ability to manage viral diseases (1-6). While not yet widely available for SARS-CoV-2, quantitative assays could advance our understanding of COVID-19 biology and inform infection prevention and control measures (7, 8). Most SARS-CoV-2 molecular diagnostic assays however, which use real-time reverse transcriptase PCR (RT-PCR) to detect one or more SARS-CoV-2 genomic targets using sequence-specific primers coupled with a fluorescent probe, are only semi-quantitative. These tests produce cycle threshold (C_t) values as readouts, which represent the PCR cycle where the sample began to produce fluorescent signal above background. While each C_t value decrement corresponds to a roughly two-fold higher viral load (due to the exponential nature of PCR amplification), C_t values cannot be directly interpreted as SARS-CoV-2 viral loads without calibration to a quantitative standard (9). Rather, C_t values are interpreted as positive, indeterminate or negative based on assay-specific cutoffs and evolving clinical guidelines. Due to differences in nucleic acid extraction method, viral target and other parameters, C_t values are also not directly comparable across assays or technology platforms.

Reverse transcriptase droplet digital PCR (RT-ddPCR) offers an attractive platform for SARS-CoV-2 RNA quantification (10, 11). Like real-time RT-PCR, ddPCR employs target-specific primers coupled with a fluorescent probe, making it relatively straightforward to adapt assays. In ddPCR however, each reaction is fractionated into 20,000 nanolitre-sized droplets prior to massively parallel PCR amplification. At end-point, each droplet is categorized as positive (target present) or negative (target absent), allowing for absolute target quantification using Poisson statistics. This sensitive and versatile technology has been used for mutation detection and copy number determination in the human genome (12), target verification

93 following genome editing (13), and copy number quantification for viral pathogens (14-19).
 94 Several real-time RT-PCR SARS-CoV-2-specific primer/probe sets have been used in RT-
 95 ddPCR (10, 11, 20-22) with results achieving high sensitivity in some reports (11, 21, 23-25), but
 96 few studies have rigorously evaluated SARS-CoV-2-specific primer/probe set performance in
 97 RT-ddPCR using RNA as a template. Furthermore, no studies to our knowledge have calibrated
 98 SARS-CoV-2 viral loads to diagnostic test C_t values. Here, we evaluate eight SARS-CoV-2-
 99 specific primer/probe sets originally developed for real-time RT-PCR (26), for use in RT-
 100 ddPCR. We also derive a linear equation relating RT-ddPCR-derived SARS-CoV-2 viral loads
 101 and real-time RT-PCR-derived C_t values for a commercial diagnostic assay, the LightMix®
 102 Modular SARS-CoV (COVID19) E-gene assay, allowing conversion of existing COVID-19
 103 diagnostic results to viral loads.

Materials and Methods

Primer and Probe Sets

Eight SARS-CoV-2-specific primer/probe sets developed for real-time RT-PCR COVID-19 diagnostic assays (26) were assessed for use in RT-ddPCR (Table 1). These included the Charité-Berlin E gene ('E-Sarbeco') set (27), the Pasteur Institute RdRp IP2 and IP4 sets ('IP2' and 'IP4', respectively) (28), the Chinese Centre for Disease Control ORF and N gene sets ('China-ORF' and 'China-N', respectively) (29), the Hong Kong University ORF and N gene sets ('HKU-ORF' and 'HKU-N', respectively) (30), and the US-CDC-N1 set (31).

SARS-CoV-2 Synthetic RNA standards

RT-ddPCR assays were evaluated using commercial synthetic SARS-CoV-2 RNA standards comprising six non-overlapping 5,000 base fragments of equal quantities encoding the Wuhan-Hu-1 SARS-CoV-2 genome (Control 2, Genbank ID MN908947.3; Twist Biosciences, supplied at approximately 1 million copies/fragment/μl). To avoid degradation, RNA standards were stored at -80°C and thawed only once, immediately before use, to perform the analytical efficiency, precision, analytical sensitivity and dynamic range analyses described herein. Moreover, to mimic nucleic acid composition of a real biological specimen, all assays employing these standards were supplemented with a consistent, physiologically relevant amount of nucleic acid extracted from pooled remnant SARS-CoV-2-negative nasopharyngeal swabs (Supplementary Figure 1). Briefly, pooled viral transport medium was extracted in 1ml aliquots on the BioMerieux NucliSens® EasyMag®, eluted in 60μl and re-pooled. The resulting material contained DNA from on average 2,200 human cells/μl (as quantified using human RPP30 DNA copy numbers by ddPCR as described in (32)) and 4,400 human RNase P copies/μl extract (as

quantified by RT-ddPCR as described in (33)), concentrations that are in line with human DNA and RNA levels recovered on nasopharyngeal swabs (32, 33).

Reverse transcriptase droplet digital PCR (RT-ddPCR) for SARS-CoV-2 quantification

RT-ddPCR reactions were performed by combining relevant SARS-CoV-2 RNA template with target-specific primers and probe (900nM and 250nM, respectively, Integrated DNA Technologies; Table 1), One-Step RT-ddPCR Advanced Kit for Probes Supermix, Reverse Transcriptase and DTT (300nM) (all from BioRad), XhoI restriction enzyme (New England Biolabs), background nucleic acid (for reactions employing synthetic RNA template only, see above) and nuclease free water. Droplets were generated using an Automated Droplet Generator (BioRad) and cycled under primer/probe set-specific conditions (see below and Figure 1). Analysis was performed on a QX200 Droplet Reader (BioRad) using QuantaSoft software (BioRad, version 1.7.4).

Thermal cycling temperature optimization

For each primer/probe set, acceptable thermal cycling temperature ranges for reverse transcription (RT) and PCR annealing/extension were determined by modifying the manufacturer-recommended default conditions, which are 42-50°C for 1 hour (for reverse transcription); 95°C for 10 minutes; 40 cycles of (94°C for 30 seconds followed by 50-63°C for 1 minute); 98°C for 10 minutes and 4°C infinite hold. To determine acceptable temperature ranges for reverse transcription, a thermal gradient from 42-51.5°C was performed while fixing the annealing/extension step at 52°C. Using the optimized reverse transcription temperature, a thermal gradient from 50-63°C was then performed to identify acceptable annealing/extension temperature ranges. Temperatures that produced insufficient separation of positive from negative droplets or non-specific amplification were deemed unacceptable, as were those that produced

consecutive 95% confidence intervals of copy number estimates outside those of the maximal point-estimate.

Analytical Efficiency and Precision

The analytical efficiency of each primer/probe set to quantify SARS-CoV-2 RNA by RT-ddPCR was determined using synthetic SARS-CoV-2 RNA standards at 1000 and 100 input copies. A minimum of three (maximum four) technical replicates were performed at each concentration. Analytical efficiency was calculated by dividing the measured SARS-CoV-2 copy number by the expected input copy number, and multiplying by 100. Precision was expressed as the coefficient of variation (CV), expressed as a percentage, across technical replicates.

Linear Dynamic Range

The linear dynamic range (LDR) of each primer/probe set of interest was determined across a serial 1:2 dilution series from 114,286 to 1.2 SARS-CoV-2 RNA copies/reaction. This range of concentrations was chosen as it crosses the entire range of recommended input copies for a ddPCR reaction seeking to quantify the target of interest (34). Reactions were performed in duplicate. The upper and lower limits of quantification of (ULOQ and LLOQ, respectively) were defined as the upper and lower boundaries of the concentration range over which the relationship between measured and input SARS-CoV-2 RNA copies was linear. This was determined by iteratively restricting the range of concentrations included in the linear regression of measured versus input SARS-CoV-2 RNA copies to identify that which maximized the coefficient of determination (R^2) value and minimized the residuals.

Assay Analytical Sensitivity

Assay analytical sensitivity, defined as the Lower Limit of Detection (LLOD), was determined for primer/probe sets of interest by serially diluting synthetic SARS-CoV-2 RNA

standards to between 47.6 and 0.74 SARS-CoV-2 RNA copies/reaction. Between 6 and 18 technical replicates were performed for each dilution and results were analyzed using probit regression. The LLOD, determined through interpolation of the probit curve, was defined as the concentration of input SARS-CoV-2 RNA in a reaction where the probability of detection was 95%.

SARS-CoV-2 RNA quantification in biological specimens, and relationship to C_t value

Optimized RT-ddPCR assays were applied to a convenience sample of 48 consecutive remnant SARS-CoV-2-positive diagnostic nasopharyngeal swab specimens that were originally submitted to the St. Paul's Hospital Virology Laboratory in Vancouver, Canada for diagnostic testing using the Roche cobas® SARS-CoV-2 assay. For these samples, total nucleic acids were re-extracted from 250µl remnant media using the BioMerieux NucliSens® EasyMag® and eluted in 50µl. Eluates were aliquoted and frozen at -80°C prior to single use. SARS-CoV-2 copy numbers were quantified by RT-ddPCR as described above. As our main goal was to characterize the relationship between C_t values and SARS-CoV-2 RNA levels without confounding by extraction platform, quantity of input material or SARS-CoV-2 genomic target, we re-tested these extracts using a commercial real-time RT-PCR SARS-CoV-2 diagnostic assay that uses the E-Sarbeco primer/probe set (27): the LightMix® 2019-nCoV real-time RT-PCR assay E-gene target (Tib-Molbiol), implemented on LightCycler 480 (Roche Diagnostics). Finally, to be responsive to a recent recommendation that SARS-CoV-2 viral loads be reported in terms of SARS-CoV-2 RNA copies per human cell equivalents (9), we measured human cells/µl extract by ddPCR as previously described (32) and additionally reported results as SARS-CoV-2 RNA copies/1,000 human cells.

Statistical Analysis

197 Statistical analysis was performed using GraphPad Prism (Version 8) or Microsoft Excel
198 (Version 14.7.2).

199 **Ethical Approval**

200 This study was approved by the Providence Health Care/University of British Columbia
201 and Simon Fraser University Research Ethics Boards under protocol H20-01055.

202

Results

Thermal cycling optimization for SARS-CoV-2 quantification by RT-ddPCR

Eight primer/probe sets originally developed for SARS-CoV-2 diagnostic testing by real time RT-PCR were evaluated for use in RT-ddPCR (Table 1). As these primer/probe sets vary in sequence, amplicon length and SARS-CoV-2 genomic target, we first determined the acceptable temperature ranges for reverse transcription (RT) and PCR annealing/extension. Most primer/probe sets were tolerant to a wide temperature range, and background signal was essentially zero at all temperatures tested (Figure 1). The E-Sarbeco primer/probe set for example produced consistent amplitude profiles, copy number estimates and essentially zero background at annealing/extension temperatures ranging from 50-63°C (Figure 1A and data not shown). The HKU-ORF primer/probe performed acceptably over a 50-60.5°C annealing/extension range, but positive and negative droplet separation was insufficient at higher temperatures (Figure 1B). Acceptable temperature ranges for each primer/probe set are shown in Figure 1C. All subsequent experiments were performed at RT 42.7°C and annealing/extension 50.9°C except those for HKU-ORF and US-CDC-N1, which were performed at RT 45.7°C and annealing/extension 55.1°C as informed by initial qualitative assessments.

Analytical Efficiency and Precision of SARS-CoV-2 quantification by RT-ddPCR

We next evaluated the analytical efficiency of SARS-CoV-2 RNA quantification for each primer/probe set, calculated as the percentage of input viral RNA copies detected by the assay. We also evaluated precision, calculated as the dispersion of measured copies around the mean (coefficient of variation, CV). Analytical efficiency and precision were evaluated at 1000 and 100 SARS-CoV-2 RNA target input copies. At 1000 input copies, primer/probe set analytical efficiency ranged from 83% (E-Sarbeco) to 15% (US-CDC-N1) (Figure 2A). At 100 copies, the

analytical efficiency hierarchy was identical, with values ranging from 74% (E Sarbeco) to 12% (US-CDC-N1). Of all primer/probe sets evaluated, the E-Sarbeco, IP2 and IP4 sets had the highest analytical efficiencies by a substantial margin. At 1000 and 100 target copies, E-Sarbeco analytical efficiency was 83% (95% Total Poisson Confidence Interval [CI]: 79- 87%) and 74% (95% CI: 63- 84%), respectively; IP2, analytical efficiency was 70% (95% CI: 67- 73%) and 55% (95% CI: 46- 64%), respectively; and IP4 analytical efficiency was 69% (95% CI: 66- 72%) and 59% (95% CI: 50-69%), respectively. In contrast, analytical efficiency of the China-ORF primer/probe set was only 46% and 39% at 1000 and 100 input copies, respectively, and the analytical efficiencies of the remaining sets were less than 30% regardless of input copy number. Furthermore, while measurement precision generally decreased at the lower template concentration (35), the E-Sarbeco, IP2 and IP4 primer/probe sets were nevertheless among the most precise, with coefficients of variation (CV) of less than 5% at 1,000 input copies and less than 15% at 100 input copies (Figure 2B). Combined analytical efficiency and precision data confirmed E-Sarbeco, IP2 and IP4 as the best-performing primer/probe sets in RT-ddPCR (Figures 2C and 2D), so these were moved forward for further characterization.

Reduced analytical efficiency when IP2 and IP4 are duplexed in RT-ddPCR

As IP2 and IP4 were originally designed for duplexing in real-time RT-PCR (28), we evaluated them in duplex for RT-ddPCR. Duplexing however decreased analytical efficiency, from 70% to 52% (at 1000 input copies) and 55% to 37% (at 100 input copies) for IP2, and from 69% to 49% (at 1000 input copies) and 59% to 38% (at 100 input copies) for IP4 (Supplemental Figure 2A). Duplexing also decreased precision (Supplemental Figure 2B). For IP2, CV increased from 5% to 11% when duplexing at 1000 input copies, and from 15% to 25% when duplexing at 100 input copies. For IP4, CV increased from 4% to 7% (1000 input copies) and

from 14% to 21% (100 input copies) with duplexing. Duplexing of these reactions is therefore not recommended in RT-ddPCR, and all IP2 and IP4 assays were performed as single reactions.

Linear Dynamic Range and Limits of Quantification of SARS-CoV-2 RNA by RT-ddPCR

Droplet digital PCR can achieve absolute target copy number quantification without a standard curve. To investigate the linear dynamic range (LDR) of quantification of the E-Sarbeco, IP2 and IP4 assays, we set up 18 two-fold serial dilutions of synthetic SARS-CoV-2 RNA beginning at 114,286 copies/reaction (this copy number is obtained when 120,000 copies are added to a 21µl reaction, of which 20µl is used for droplet generation) and ending with 2.32 copies/reaction. This input copy number range crosses nearly the entire manufacturer-recommended template input range for ddPCR reactions seeking to quantify the target of interest, which is 1- 100,000 copies/reaction (36).

The LDR of each assay was determined by iteratively restricting the range of concentrations included in the linear regression of measured versus input SARS-CoV-2 RNA copies to identify the range that maximized the R^2 value and minimized the residuals. For E-Sarbeco, the regression spanning 18.6-114,286 input SARS-CoV-2 RNA copies per reaction, an approximately 6,100-fold concentration range, yielded an R^2 value of 0.9995 (Figure 3A, left). Restricting the linear regression to this range also minimized the residuals of all included data points to $\pm 0.065 \log_{10}$ copies/reaction (Figure 3A, right). The IP2 assay, while less efficient than E-Sarbeco, had the same estimated LDR of 18.6-114,286 input copies/reaction (Figure 3B, left). This produced an R^2 value of 0.9995 and residuals within $\pm 0.065 \log_{10}$ copies/reaction across the LDR (Figure 3B, right). The LDR of IP4 was estimated as 37.2- 114,286 input copies/reaction, an approximately 3,000-fold range, which yielded an $R^2 = 0.9975$ and produced residuals within $\pm 0.11 \log_{10}$ copies/reaction across this range (Figure 3C). For all three assays, 114,286 input

copies/reaction should be considered a conservative estimate of the upper limit of quantification, as saturation of the RT-ddPCR reaction or loss of linearity was still not achieved at this concentration.

Lower Limit of Detection of SARS-CoV-2 RNA by RT-ddPCR

We next determined the lower limit of detection (LLOD) of the E-Sarbeco, IP2 and IP4 RT-ddPCR assays (Figure 4). Probit regression analysis applied to serial dilutions of synthetic SARS-CoV-2 RNA standards revealed the E-Sarbeco RT-ddPCR assay to be the most analytically sensitive of the three, which is consistent with it also having the highest analytical efficiency. Specifically, the estimated LLOD of the E-Sarbeco assay was 4.4 (95% Confidence Interval [CI]: 2.4-5.7) SARS-CoV-2 RNA copies/reaction (Figure 4A). The estimated LLOD of the IP2 assay was 7.8 (95% CI: 4.4-10.3) SARS-CoV-2 RNA copies/reaction (Figure 4B), while that of IP4 was 12.6 (95% CI: 6.9-16.5) SARS-CoV-2 RNA copies per reaction (Figure 4C).

SARS-CoV-2 viral loads in biological samples

SARS-CoV-2 viral loads were measured in 48 confirmed SARS-CoV-2 positive samples using the E-Sarbeco, IP2 and IP4 primer/probe sets (note that samples with original diagnostic test C_t values <19 required RNA extracts to be diluted up to 1:200 prior to quantification to ensure that input copies measurements fell within each assay's LDR). The results revealed that SARS-CoV-2 RNA in these biological samples varied over a 6.2 $\log_{10}$ range (Figure 5A). Average copy numbers measured using the E-Sarbeco assay (which targets the E gene) were higher than those using the IP2 and IP4 assays (which target ORF1a and ORF1b, respectively) (Figure 5A). This is consistent with assay analytical efficiency (Figure 2) and *in vivo* coronavirus RNA expression patterns, where transcripts covering the 3' end of the genome are more abundant than those covering the 5' end (37-40). Specifically, the median E-gene copy number

was 5.1 (IQR 3.9- 5.7) $\log_{10}$ copies/ μ l extract compared to a median of 4.9 (IQR 3.9- 5.5) $\log_{10}$ copies/ μ l extract for the IP2 target, and a median of 4.9 (IQR 3.9- 5.6) $\log_{10}$ copies/ μ l extract for the IP4 target. SARS-CoV-2 E-gene, IP2 and IP4 copy numbers in biological samples correlated strongly with one another (Spearman's $\rho > 0.99$; $p < 0.0001$ for all pairwise analyses; Figure 5BCD). Consistent with comparable ORF1a and ORF1b RNA transcript levels *in vivo* (37, 38, 40), IP2 and IP4 copy numbers were also highly concordant (Lin's concordance correlation coefficient, $\rho_c = 0.9996$ [95% CI: 0.9993- 0.9998]) (Figure 5D). Based on a recent recommendation (9), we also report our results in terms of SARS-CoV-2 RNA copies per human cell equivalents: results for E-Sarbeco spanned an 7-fold range from 1.05 to 7.3 $\log_{10}$ SARS-CoV-2 RNA copies/1,000 human cells, with IP2 and IP4 $\log_{10}$ copy numbers lower, as expected (Supplemental Figure 3A). The Spearman's correlation between absolute and human cell-normalized viral loads was strong ($\rho = 0.9717$; $p < 0.0001$; Supplementary Figure 3B), which is consistent with the assumption that the amount of biological material collected by nasopharyngeal swabs is relatively consistent.

Inferring SARS-CoV-2 viral loads from diagnostic C_t values

Finally, we characterized the relationship between C_t values produced by a commercial COVID-19 diagnostic platform and SARS-CoV-2 RNA copy numbers. We selected the LightMix® 2019-nCoV real-time RT-PCR assay, E-gene target (Tib-Molbiol), implemented on a LightCycler 480 (Roche Diagnostics) because commercial diagnostic reagents comprising the E-Sarbeco primer/probe set exist for this platform (27) and because it takes purified nucleic acids as input, thereby allowing direct comparison of results from the same starting material (real-time RT-PCR platforms that take biological material as input are suboptimal for such a comparison because the onboard extraction introduces an additional variable). As the C_t values reported for

the LightMix® assay are based on a 9µl extract input volume, our primary analysis reported RT-ddPCR results in terms of SARS-CoV-2 copies equivalent (*i.e.* SARS-CoV-2 copies in 9µl of extract), to allow direct conversion of C_t values to absolute viral copy numbers.

Sample C_t values ranged from 11.34-31.18 (median 18.69 [IQR 16.73- 22.69]) using the LightMix® assay. The relationship between C_t value and SARS-CoV-2 RNA copy numbers was log-linear, with an $R^2 = 0.9990$ (Figure 6). Despite this strong relationship, inspection of the residuals nevertheless suggested modest departures from log-linearity at the extremes of the linear range (Supplementary Figure 4). The relationship between C_t value and absolute SARS-CoV-2 E-gene copies can thus be given by $\log_{10}\text{SARS-CoV-2 E gene copies equivalent} = -0.3038C_t + 11.7$ (Figure 6). That is, a C_t value of 20 corresponds to 453,942 (*i.e.* $5.66 \log_{10}$) SARS-CoV-2 RNA copies, while a C_t value of 30 corresponds to 416 (*i.e.* $2.62 \log_{10}$) viral copies. This equation also predicts that the C_t values corresponding to the LLOQ and LLOD of the E-Sarbeco RT-ddPCR assays are 34.8 and 36.84, respectively. When measured SARS-CoV-2 RNA copy numbers are expressed as human cell-normalized viral loads, the relationship with C_t value is given by $\log_{10}\text{SARS-CoV-2 E gene copies}/1,000 \text{ human cells} = -0.3041C_t + 10.8$ (Supplemental Figure 5). An extract that yielded a C_t value of 20 therefore is estimated to have contained 48,978 (*i.e.* $4.69 \log_{10}$) SARS-CoV-2 RNA copies/1,000 human cells, while one with C_t value of 30 is estimated to have contained 45 (*i.e.* $1.66 \log_{10}$) copies/1,000 human cells

Discussion

While real-time and droplet digital RT-PCR platforms both employ target-specific primers coupled with fluorescence-based amplicon detection, there are key differences in reaction chemistry (*e.g.* RT-ddPCR reagents must be compatible with water-in-oil droplet

partitioning) and probe chemistry (*e.g.* while real-time RT-PCR uses fluorescent quenchers, ddPCR typically uses dark quenchers). As a result, assays developed for one platform may not always translate seamlessly to the other. For example, ddPCR probes should ideally not have a Guanine at their 5' end because this quenches the fluorescence signal even following hydrolysis (36) but the HKU-N probe has a G at its 5' end (Table 1).

It is perhaps therefore not surprising that the overall performance of the eight primer/probe sets in RT-ddPCR did not exactly mirror that in real-time RT-PCR (41, 42). Nevertheless, E-Sarbeco, IP2 and IP4, which represented the most efficient and precise primer/probe sets for SARS-CoV-2 RNA quantification by RT-ddPCR are also among the most efficient in real-time RT-PCR (41, 42). Our results also confirm previous reports of the E-Sarbeco primer/probe set performing well in RT-ddPCR (10, 22). Other primer/probe sets however, notably US CDC-N1, HKU-ORF and China-ORF, did not perform as well in our RT-ddPCR assay compared to a previous report (10). One key difference is that, while we used sequence-specific reverse transcription (with the reverse primer) in a one-step RT-ddPCR reaction, the previous study featured an independent reverse transcription reaction primed with random hexamers and oligo dT, which can yield higher efficiency than sequence-specific priming (35, 43-45), to generate cDNA for input into a ddPCR reaction. To our knowledge, ours is the first study to evaluate IP2 or IP4 primer/probe sets in RT-ddPCR.

The analytical sensitivities of the RT-ddPCR assays reported here are nevertheless comparable to existing estimates. The limit of detection of the BioRad SARS-CoV-2 ddPCR Kit (20) is, for example, estimated at 150 copies/mL, which is comparable to our E-Sarbeco RT-ddPCR assay (estimated at 75.8 copies/mL assuming 100% extraction efficiency). Similarly, the LLODs of the TargetingOne (Beijing, China) COVID-19 digital PCR detection kit (23) and a

multiplex assay that included the E-Sarbeco primer/probe set (22) were reported at 10 copies/test and 5 copies/reaction, respectively, both comparable to the LLOD determined here. While a number of studies have reported that RT-ddPCR can detect SARS-CoV-2 RNA in low viral load clinical samples with higher sensitivity than real-time RT-PCR (11, 21, 23-25), our study was not designed to evaluate this. Our estimated LLOD of 4.4 copies/reaction by RT-ddPCR using the E-Sarbeco primer/probe set (Figure 4) is in fact comparable to the LLOD reported for many real-time RT-PCR-based COVID-19 diagnostic assays (46).

The ability to quantify SARS-CoV-2 viral loads in biological samples can advance our understanding of COVID-19 biology, and RT-ddPCR offers an attractive platform (7, 8). Our observation that, in a small convenience sample, both absolute and human cell-normalized (9) SARS-CoV-2 loads spanned a more than 6 $\log_{10}$ range confirms an enormous viral load range *in vivo* (47) and suggests that some of the high viral load samples measured here were from individuals with early and progressive infection (23, 48-50) or who were experiencing severe disease (7, 8), though clinical information was unknown. Furthermore, our equation relating C_t values derived from a commercial diagnostic assay and SARS-CoV-2 RNA copy number means that existing diagnostic test results can be converted to viral loads *without re-testing samples*. While calibration of viral load measurements against all real-time RT-PCR platforms is beyond our scope, this is achievable and in some cases data may already be available (23).

Some limitations merit mention. We only tested eight commonly-used SARS-CoV-2-specific primer/probe sets, and others may exist that adapt well to RT-ddPCR. Our assay performance estimates should be considered approximate, as the manufacturer-reported concentration of the synthetic SARS-CoV-2 RNA standards used in our study may vary by up to 20% error (Twist Bioscience, personal communication). Moreover, we solely evaluated a one-

step RT-ddPCR protocol, and therefore assay performance estimates will likely differ from protocols that feature independent cDNA generation followed by ddPCR. We could not precisely define the upper boundary of the linear dynamic range of the E-Sarbeco, IP2 and IP4 RT-ddPCR assays as linearity was maintained at the maximum input of 114,286 target copies/reaction, which already exceeds the manufacturer's estimated upper range of quantification in a ddPCR reaction (36). Our convenience panel of 48 SARS-CoV-2-positive diagnostic specimens also likely did not capture the full range of biological variation in viral loads, though data from larger cohorts (47) suggests that it was reasonably comprehensive. We also acknowledge that there is measurement uncertainty with real-time RT-PCR C_t values that may subtly affect the linear relationship between C_t value and RT-ddPCR-derived SARS-CoV-2 viral load described here. Finally, our estimates of assay performance may not completely reflect those of the entire diagnostic process, as the nucleic acid extraction step introduces additional inefficiencies.

In conclusion, primer/probe sets used in real-time RT-PCR-based COVID-19 diagnostic tests can be migrated to RT-ddPCR to achieve SARS-CoV-2 RNA quantification with varying analytical efficiency, precision and sensitivity. Of the primer/probe sets tested, the E-Sarbeco, IP2 and IP4 sets performed best, where LLOQ and LLOD estimates for the E-Sarbeco assay (18.6 and 4.4 copies/reaction, respectively) indicated that RT-ddPCR and real-time RT-PCR have comparable sensitivity. Mathematical inference of SARS-CoV-2 copy numbers from COVID-19 diagnostic test C_t values, made possible via the type of calibration performed in the present study, will allow the wealth of existing diagnostic test data to be harnessed to answer foundational questions in SARS-CoV-2 biology.

Acknowledgements

410 This work was supported by a COVID-19 rapid response grant from GenomeBC
411 (COVID-115; to ZLB and CFL) and CIHR project grant (PJT-159625; to ZLB). NNK is
412 supported by a Vanier Canada Graduate Scholarship. ZLB holds a Scholar Award from the
413 Michael Smith Foundation for Health Research.
414
415

References

1. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* 272:1167-70.
2. Mellors JW. 1998. Viral-load tests provide valuable answers. *Sci Am* 279:90-3.
3. Riddler SA, Mellors JW. 1997. HIV-1 viral dynamics and viral load measurement: implications for therapy. *AIDS Clin Rev*:47-65.
4. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR, Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 126:946-54.
5. Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. 2009. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. *Clin Infect Dis* 49:498-506.
6. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. 2006. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. *Am J Gastroenterol* 101:1797-803.
7. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, L'Honneur AS, Rozenberg F, Laurent-Puig P, Bélec L, Hadjadj J, Terrier B, Péré H. 2020. Highly sensitive quantification of plasma SARS-CoV-2 RNA sheds light on its potential clinical value. *Clin Infect Dis* doi:10.1093/cid/ciaa1196.
8. Bermejo-Martin JF, González-Rivera M, Almansa R, Micheloud D, Tedim AP, Domínguez-Gil M, Resino S, Martín-Fernández M, Murua PR, Pérez-García F, Tamayo L, Lopez-Izquierdo R, Bustamante E, Aldecoa C, Gómez JM, Rico-Feijoo J, Orduña A, Méndez R, Fernández Natal I, Megías G, González-Estecha M, Carriedo D, Doncel C, Jorge N, Ortega A, de la Fuente A, del Campo F, Fernández-Ratero JA, Trapiello W, González-Jiménez P, Ruiz G, Kelvin AA, Ostadgavahi AT, Oneizat R, María Ruiz L, Miguéns I, Gargallo E, Muñoz I, Pelegrin S, Martín S, García Olivares P, Cedeño JA, Albi TR, Puertas C, Ángel Berezo J, Renedo G, Herrán R, Bustamante-Munguira J, Enríquez P, Cicuendez R, et al. 2020. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. *medRxiv* doi:10.1101/2020.08.25.20154252:2020.08.25.20154252.
9. Han MS, Byun JH, Cho Y, Rim JH. 2020. RT-PCR for SARS-CoV-2: quantitative versus qualitative. *Lancet Infect Dis* doi:10.1016/s1473-3099(20)30424-2.
10. Liu X, Feng J, Zhang Q, Guo D, Zhang L, Suo T, Hu W, Guo M, Wang X, Huang Z, Xiong Y, Chen G, Chen Y, Lan K. 2020. Analytical comparisons of SARS-CoV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets. *Emerg Microbes Infect* 9:1175-1179.
11. Suo T, Liu X, Feng J, Guo M, Hu W, Guo D, Ullah H, Yang Y, Zhang Q, Wang X, Sajid M, Huang Z, Deng L, Chen T, Liu F, Xu K, Liu Y, Zhang Q, Liu Y, Xiong Y, Chen G, Lan K, Chen Y. 2020. ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. *Emerg Microbes Infect* 9:1259-1268.
12. BioRad-Laboratories-Inc. 2020. Wet-Lab Validated ddPCR Assays for Mutation Detection and Copy Number Determination. https://www.biorad.com/webroot/web/pdf/lsr/literature/Bulletin_7144.pdf. Accessed

13. BioRad-Laboratories-Inc. 2019. Direct Quantification of Genome Editing Efficiency from Whole Cells Using SingleShot Cell Lysis Buffer and ddPCR Genome Edit Detection Assays. https://www.biorad.com/webroot/web/pdf/lsr/literature/Bulletin_7155.pdf. Accessed
14. Lillsunde Larsson G, Helenius G. 2017. Digital droplet PCR (ddPCR) for the detection and quantification of HPV 16, 18, 33 and 45 - a short report. *Cell Oncol (Dordr)* 40:521-527.
15. Stevenson A, Wakeham K, Pan J, Kavanagh K, Millan D, Bell S, McLellan D, Graham SV, Cuschieri K. 2020. Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours. *J Clin Virol* 129:104505.
16. Cao WW, He DS, Chen ZJ, Zuo YZ, Chen X, Chang YL, Zhang ZG, Ye L, Shi L. 2020. Development of a droplet digital PCR for detection and quantification of porcine epidemic diarrhea virus. *J Vet Diagn Invest* 32:572-576.
17. Persson S, Eriksson R, Lowther J, Ellström P, Simonsson M. 2018. Comparison between RT droplet digital PCR and RT real-time PCR for quantification of noroviruses in oysters. *Int J Food Microbiol* 284:73-83.
18. Pinheiro-de-Oliveira TF, Fonseca AA, Jr., Camargos MF, Laguardia-Nascimento M, de Oliveira AM, Cottorello ACP, Goes-Neto A, Barbosa-Stancioli EF. 2018. Development of a droplet digital RT-PCR for the quantification of foot-and-mouth virus RNA. *J Virol Methods* 259:129-134.
19. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF. 2019. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature* 566:120-125.
20. BioRad-Laboratories-Inc. 2020. Bio-Rad SARS-CoV-2 ddPCR Kit, Qualitative assay for use in the QX200 and QXDx Droplet Digital PCR Systems Instructions for Use.
21. Falzone L, Musso N, Gattuso G, Bongiorno D, Palermo CI, Scalia G, Libra M, Stefani S. 2020. Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. *Int J Mol Med* 46:957-964.
22. de Kock R, Baselmans M, Scharnhorst V, Deiman B. 2020. Sensitive detection and quantification of SARS-CoV-2 by multiplex droplet digital RT-PCR. *Eur J Clin Microbiol Infect Dis* doi:10.1007/s10096-020-04076-3:1-7.
23. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. 2020. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin Infect Dis* 71:793-798.
24. Alteri C, Cento V, Antonello M, Colagrossi L, Merli M, Ughi N, Renica S, Matarazzo E, Di Ruscio F, Tartaglione L, Colombo J, Grimaldi C, Carta S, Nava A, Costabile V, Baiguera C, Campisi D, Fanti D, Vismara C, Fumagalli R, Scaglione F, Epis OM, Puoti M, Perno CF. 2020. Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. *PLoS One* 15:e0236311.
25. Dang Y, Liu N, Tan C, Feng Y, Yuan X, Fan D, Peng Y, Jin R, Guo Y, Lou J. 2020. Comparison of qualitative and quantitative analyses of COVID-19 clinical samples. *Clin Chim Acta* 510:613-616.

26. World-Health-Organization. 2020. Summary of Available SARS-CoV-2 RT-PCR protocols.
27. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25.
28. Institut-Pasteur-Paris. 2020. Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2.
29. Chinese-National-Institute-for-Viral-Disease-Control-and-Prevention. 2020. Specific primers and probes for detection of 2019 novel coronavirus.
30. School-of-Public-Health-LKS-Faculty-of-Medicine-University-of-Hong-Kong. 2020. Detection of 2019 novel coronavirus (2019-nCoV) in suspected human cases by RT-PCR.
31. Centers-for-Disease-Control-and-Prevention. 2020. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.
32. Kinloch NN, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Jones RB, Montaner JSG, Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF, Brumme ZL. 2020. Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. *The Journal of Infectious Diseases* doi:10.1093/infdis/jiaa370.
33. Kinloch NN, Shahid A, Ritchie G, Dong W, Lawson T, Montaner JSG, Romney MG, Stefanovic A, Matic N, Brumme CJ, Lowe CF, Brumme ZL, Leung V. 2020. Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. *Open Forum Infect Dis* 7:ofaa488.
34. Bio-Rad-Laboratories-Inc. 2019. Droplet Digital PCR Applications Guide.
35. Schwaber J, Andersen S, Nielsen L. 2019. Shedding light: The importance of reverse transcription efficiency standards in data interpretation. *Biomol Detect Quantif* 17:100077.
36. BioRad-Laboratories-Inc. 2019. Droplet Digital PCR Applications Guide. https://www.bio-rad.com/webroot/web/pdf/lsl/literature/Bulletin_6407.pdf. Accessed
37. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. 2020. The Architecture of SARS-CoV-2 Transcriptome. *Cell* 181:914-921.e10.
38. Irigoyen N, Firth AE, Jones JD, Chung BY, Siddell SG, Brierley I. 2016. High-Resolution Analysis of Coronavirus Gene Expression by RNA Sequencing and Ribosome Profiling. *PLoS Pathog* 12:e1005473.
39. Dimmock NJ, Easton AJ, Leppard KN. 2007. *Introduction to Modern Virology*, 6 ed. Blackwell Publishing.
40. Davidson AD, Williamson MK, Lewis S, Shoemark D, Carroll MW, Heesom KJ, Zambon M, Ellis J, Lewis PA, Hiscox JA, Matthews DA. 2020. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. *Genome Med* 12:68.

41. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, Petrone ME, Casanovas-Massana A, Catherine Muenker M, Moore AJ, Klein J, Lu P, Lu-Culligan A, Jiang X, Kim DJ, Kudo E, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Tokuyama M, Venkataraman A, Weizman OE, Wong P, Yang Y, Cheemarla NR, White EB, Lapidus S, Earnest R, Geng B, Vijayakumar P, Odio C, Fournier J, Bermejo S, Farhadian S, Dela Cruz CS, Iwasaki A, Ko AI, Landry ML, Foxman EF, Grubaugh ND. 2020. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. *Nat Microbiol* 5:1299-1305.
42. Etievant S, Bal A, Escuret V, Brengel-Pesce K, Bouscambert M, Cheynet V, Generenaz L, Oriol G, Destras G, Billaud G, Josset L, Frobert E, Morfin F, Gaymard A. 2020. Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories. *J Clin Med* 9.
43. Bustin SA, Benes V, Nolan T, Pfaffl MW. 2005. Quantitative real-time RT-PCR--a perspective. *J Mol Endocrinol* 34:597-601.
44. Sanders R, Mason DJ, Foy CA, Huggett JF. 2013. Evaluation of digital PCR for absolute RNA quantification. *PLoS One* 8:e75296.
45. Levesque-Sergerie JP, Duquette M, Thibault C, Delbecchi L, Bissonnette N. 2007. Detection limits of several commercial reverse transcriptase enzymes: impact on the low- and high-abundance transcript levels assessed by quantitative RT-PCR. *BMC Mol Biol* 8:93.
46. Lai CC, Wang CY, Ko WC, Hsueh PR. 2020. In vitro diagnostics of coronavirus disease 2019: Technologies and application. *J Microbiol Immunol Infect* doi:10.1016/j.jmii.2020.05.016.
47. Jacot D, Greub G, Jaton K, Opota O. 2020. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. *Microbes Infect* doi:10.1016/j.micinf.2020.08.004.
48. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis* 20:411-412.
49. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med* 382:1177-1179.
50. Huang Y, Chen S, Yang Z, Guan W, Liu D, Lin Z, Zhang Y, Xu Z, Liu X, Li Y. 2020. SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients. *Am J Respir Crit Care Med* 201:1435-1438.

Source	Name	Gene Target	Primer/ Probe	Sequence ^φ (5'→3')	Coordinates ^ψ
Charité-Berlin	E-Sarbeco	E	Fwd Primer	ACAGGTACGTTAATAGTTAATAGCGT	26,269- 26,294
			Rev Primer	ATATTGCAGCAGTACGCACACA	26,381- 26,360
			Probe	FAM-ACACTAGCC/ZEN/ATCCTTACTGCGCTTCG-3IABkFQ	26,332- 26,357
Pasteur Institute	IP2	ORF1a	Fwd Primer	ATGAGCTTAGTCCTGTTG	12,690- 12,707
			Rev Primer	CTCCCTTTGTTGTGTTGT	12,797- 12,780
			Probe	HEX-AGATGTCTT/ZEN/GTGCTGCCGGTA-3IABkFQ	12,717- 12,737
	IP4	ORF1b	Fwd Primer	GGTAACTGGTATGATTTTCG	14,080- 14,098
			Rev Primer	CTGGTCAAGGTTAATATAGG	14,105- 14,123
			Probe	FAM-TCATACAAA/ZEN/CCACGCCAGG-3IABkFQ	14,186- 14,167
China CDC	China-ORF	ORF1a	Fwd Primer	CCCTGTGGGTTTTACACTTAA	13,342- 13,362
			Rev Primer	ACGATTGTGCATCAGCTGA	13,460- 13,442
			Probe	FAM-CCGTCTGCG/ZEN/GTATGTGGAAAGGTTATGG-3IABkFQ	13,377- 13,404
	China-N	N	Fwd Primer	GGGGAAGTTCTCCTGCTAGAAT	28,881- 28,902
			Rev Primer	CAGACATTTTGCTCTCAAGCTG	28,979- 28,958
			Probe	FAM-TTGCTGCTG/ZEN/CTTGACAGATT-3IABkFQ	28,934- 28,953
Hong Kong University	HKU-ORF	ORF1b	Fwd Primer	TGGGGYTTTACRGGTAACCT	18,778- 18,797
			Rev Primer	AACRCGCTTAACAAAGCACTC	18,849- 18,872
			Probe	FAM-TAGTTGTGA/ZEN/TGCWATCATGACTAG-3IABkFQ	18,909- 18,889
	HKU-N	N	Fwd Primer	TAATCAGACAAGGAAGTATTA	29,145- 29,166
			Rev Primer	CGAAGGTGTGACTTCCATG	29,179- 29,198
			Probe	FAM-GCAAATTGT/ZEN/GCAATTTGCGG-3IABkFQ	29,254- 29,236
US CDC	US-CDC-N1	N	Fwd Primer	GACCCCAAAATCAGCGAAAT	28,287- 28,306
			Rev Primer	TCTGGTTACTGCCAGTTGAATCTG	28,358- 28,335
			Probe	FAM-ACCCCGCAT/ZEN/TACGTTTGGTGGACC-3IABkFQ	28,309- 28,332

^φ FAM= 6-Carboxyfluorescein; HEX= Hexachloro-Fluorescein; ZEN= internal ZEN quencher (Integrated DNA Technologies); 3IABkFQ= 3' Iowa Black Black Hole Quencher (Integrated DNA Technologies)

^ψ Coordinates based on the SARS-CoV-2 Wuhan-Hu-1 genome (Genbank Accession Number: MN908947.3)

Figure 1: Thermal cycling optimization (A). RT-ddPCR plots for annealing/extension under a 50-63°C thermal gradient for the E-Sarbeco primer/probe set. A representative RT-ddPCR plot for a no template control (NTC) which only included non-target DNA/RNA (see methods) at the temperature used in subsequent experiments, is also shown. Positive droplets (blue) are above the threshold (pink line); negative droplets (grey) are below the line. Colored boxes below each well indicate if results met standards for inclusion (green) or not (red) (see methods). (B). Same as panel A, but for HKU-ORF primer/probe set. (C). Acceptable RT and annealing/extension temperature ranges for each primer/probe set.

Figure 2: Analytical efficiency and precision of primer/probe sets. (A) Analytical efficiency of each primer/probe set, calculated as the measured divided by the input SARS-CoV-2 RNA copies multiplied by 100%, is shown for reactions containing 1,000 and 100 input copies of synthetic SARS-CoV-2 RNA. Bars represent 95% Total Poisson Confidence Intervals. (B). Precision of each primer/probe set, defined as the coefficient of variation (expressed as a percentage, CV%) of measured copies, is shown for reactions containing 1,000 and 100 input copies of synthetic SARS-CoV-2 RNA. (C). Plotting precision versus analytical efficiency at 1,000 input SARS-CoV-2 RNA copies identifies E-Sarbeco, IP2 and IP4 primer/probe sets as having analytical efficiencies >50% and CV (%) <15%. (D). Same as C, but for 100 input SARS-CoV-2 RNA copies.

Figure 3: Linear Dynamic Range (LDR) of E-Sarbeco, IP2 and IP4 RT-ddPCR assays. (A). left: $\log_{10}$ Measured SARS-CoV-2 RNA copies over serial dilutions of synthetic SARS-CoV-2 RNA standards ranging from 114,286 to 2.32 copies/reaction (shown as $\log_{10}$ values), using the

E-Sarbeco primer/probe set. Error bars indicate 95% Total Poisson Confidence Intervals for two merged replicates, where in some cases error bars are too small to visualize. The regression line joins all data points included in the LDR, where the lower boundary of the LDR represents the lower limit of quantification (LLOQ) of the assay. Data points that yielded undetectable measurements are set arbitrarily to $-0.35\log_{10}\text{Measured copies/reaction}$ for visualization. right: $\log_{10}\text{Residuals}$, calculated as $\log_{10}\text{Measured SARS-CoV-2 RNA copies/reaction}$ minus $\log_{10}\text{Calculated SARS-CoV-2 RNA copies/reaction}$ from the LDR regression. Grey shading indicates data points outside the LDR. Residuals for data points that yielded undetectable measurements are arbitrarily set to -0.4 for visualization. (B). Same as A, but for the IP2 primer/probe set (C). Same as A, but for the IP4 primer/probe set.

Figure 4: Lower Limit of Detection (LLOD) of the E-Sarbeco, IP2 and IP4 RT-ddPCR assays. (A). The probability of detecting SARS-CoV-2 RNA (%) in 1:2 in serial dilutions of synthetic SARS-CoV-2 RNA from 47.6 to 0.74 input copies/reaction using the E-Sarbeco primer/probe set is analyzed using probit regression (solid black line; dashed line denotes the 95% confidence interval). The LLOD, defined as the concentration of SARS-CoV-2 RNA in a reaction where the probability of detection in the assay was 95%, was interpolated from the standard curve and is shown as a colored dashed line (B). Same as A, but for the IP2 primer/probe set (C). Same as A, but for the IP4 primer/probe set.

Figure 5: $\log_{10}$ SARS-CoV-2 RNA loads in diagnostic specimens (A). SARS-CoV-2 E (green circles), ORF1a (red squares) and ORF1b (blue triangles) gene copy numbers, expressed as RNA copies/ μl of nucleic acid extract. Line and bars indicate median and interquartile range,

respectively. **(B)** Correlation between Log₁₀SARS-CoV-2 E and ORF1a gene RNA copies/μl extract. **(C)** Correlation between Log₁₀SARS-CoV-2 E and ORF1b gene RNA copies/μl extract. **(D)** Correlation and Concordance between Log₁₀SARS-CoV-2 ORF1a and ORF1b gene RNA copies/μl extract.

Figure 6: Relationship between SARS-CoV-2 RNA copies equivalent and diagnostic test C_t value. C_t value, determined using the LightMix® 2019-nCoV real-time RT-PCR assay (E-gene target) is plotted against log₁₀SARS-CoV-2 E gene RNA copies equivalent, which represents the number of SARS-CoV-2 RNA copies measured by RT-ddPCR in 9μl extract (the template volume in the LightMix® assay). The linear regression (solid black line) transitions to a dashed line below the LLOQ.

Supplementary Figure 1: All experiments using synthetic SARS-CoV-2 synthetic standards were performed in a consistent background of human nucleic acids to mimic a real human sample. Example experiment showing consistent levels of background human cells/μl extract (determined by dividing measured human RPP30 DNA copy number by two; black triangles), and human RNase P RNA levels (grey squares) across a titration of SARS-CoV-2 synthetic RNA standards, measured using the E-Sarbeco primer/probe set (green circles). Error bars indicate 95% Total Poisson Confidence Intervals for two merged replicates, where in some cases error bars are too small to visualize. Grey (RNase P) and black (RPP30) dashed lines indicate copies measured control experiments lacking SARS-CoV-2 RNA.

Supplementary Figure 2: Duplexing the IP2 and IP4 primer/probe sets reduces analytical efficiency and precision. (A). Analytical efficiency of SARS-CoV-2 quantification was evaluated for the IP2 and IP4 primer/probe sets when used in separate reactions (dark red and dark blue, respectively) and when duplexed (light red and light blue, respectively), in reactions containing 1,000 and 100 viral RNA input copies. Error bars represent 95% Total Poisson Confidence Intervals. (B). Same as A, but for assay precision (coefficient of variation, CV%).

Supplementary Figure 3: Log₁₀SARS-CoV-2 RNA loads in diagnostic specimens, normalized to human cells sampled. (A) SARS-CoV-2 E (green circles), ORF1a (red squares) and ORF1b (blue triangles) gene copy numbers, expressed as RNA copies/1,000 human cells. Line and bars indicate median and interquartile range, respectively. (B) Correlation between SARS-CoV-2 RNA copies/μl extract and RNA copies/1,000 human cells.

Supplemental Figure 4: Residuals of relationship between SARS-CoV-2 RNA copies equivalent and diagnostic test C_t value. Log₁₀Residuals are calculated as log₁₀Measured SARS-CoV-2 RNA copies equivalent minus log₁₀Calculated SARS-CoV-2 RNA copies equivalent from the regression line shown in Figure 6.

Supplemental Figure 5: Relationship between SARS-CoV-2 RNA copies/1,000 human cells and C_t value. Same data as shown in Figure 6, but where the measured SARS-CoV-2 RNA copies/μl extract were normalized to copies/1,000 human cells. The linear regression is shown as a solid black line.

Figure 1: Thermal cycling optimization (A). RT-ddPCR plots for annealing/extension under a 50-63°C thermal gradient for the E-Sarbeco primer/probe set. A representative RT-ddPCR plot for a no template control (NTC) which only included non-target DNA/RNA (see methods) at the temperature used in subsequent experiments, is also shown. Positive droplets (blue) are above the threshold (pink line); negative droplets (grey) are below the line. Colored boxes below each well indicate if results met standards for inclusion (green) or not (red) (see methods). (B). Same as panel A, but for HKU-ORF primer/probe set. (C). Acceptable RT and annealing/extension temperature ranges for each primer/probe set.

A **B** **C**

1000 Input SARS-CoV-2 RNA Copies

D

100 Input SARS-CoV-2 RNA Copies

Figure 2: Analytical efficiency and precision of primer/probe sets. (A) Analytical efficiency of each primer/probe set, calculated as the measured divided by the input SARS-CoV-2 RNA copies multiplied by 100%, is shown for reactions containing 1,000 and 100 input copies of synthetic SARS-CoV-2 RNA. Bars represent 95% Total Poisson Confidence Intervals. (B). Precision of each primer/probe set, defined as the coefficient of variation (expressed as a percentage, CV%) of measured copies, is shown for reactions containing 1,000 and 100 input copies of synthetic SARS-CoV-2 RNA. (C). Plotting precision versus analytical efficiency at 1,000 input SARS-CoV-2 RNA copies identifies E-Sarbeco, IP2 and IP4 primer/probe sets as having analytical efficiencies >50% and CV (%) <15%. (D). Same as C, but for 100 input SARS-CoV-2 RNA copies.

A

E-Sarbeco

B

IP2

C

IP4

Figure 3: Linear Dynamic Range (LDR) of E-Sarbeco, IP2 and IP4 RT-ddPCR assays. (A). left: $\log_{10}$ Measured SARS-CoV-2 RNA copies over serial dilutions of synthetic SARS-CoV-2 RNA standards ranging from 114,286 to 2.32 copies/reaction (shown as $\log_{10}$ values), using the E-Sarbeco primer/probe set. Error bars indicate 95% Total Poisson Confidence Intervals for two merged replicates, where in some cases error bars are too small to visualize. The regression line joins all data points included in the LDR, where the lower boundary of the LDR represents the lower limit of quantification (LLOQ) of the assay. Data points that yielded undetectable measurements are set arbitrarily to $-0.35 \log_{10}$ Measured copies/reaction for visualization. right: $\log_{10}$ Residuals, calculated as $\log_{10}$ Measured SARS-CoV-2 RNA copies/reaction minus $\log_{10}$ Calculated SARS-CoV-2 RNA copies/reaction from the LDR regression. Grey shading indicates data points outside the LDR. Residuals for data points that yielded undetectable measurements are arbitrarily set to -0.4 for visualization. (B). Same as A, but for the IP2 primer/probe set (C). Same as A, but for the IP4 primer/probe set.

A

E-Sarbeco

B

IP2

C

IP4

Figure 4: Lower Limit of Detection (LLOD) of the E-Sarbeco, IP2 and IP4 RT-ddPCR assays. (A). The probability of detecting SARS-CoV-2 RNA (%) in 1:2 in serial dilutions of synthetic SARS-CoV-2 RNA from 47.6 to 0.74 input copies/reaction using the E-Sarbeco primer/probe set is analyzed using probit regression (solid black line; dashed line denotes the 95% confidence interval). The LLOD, defined as the concentration of SARS-CoV-2 RNA in a reaction where the probability of detection in the assay was 95%, was interpolated from the standard curve and is shown as a colored dashed line (B). Same as A, but for the IP2 primer/probe set (C). Same as A, but for the IP4 primer/probe set.

A **B** **C** **D**

Figure 5: Log₁₀SARS-CoV-2 RNA loads in diagnostic specimens (A). SARS-CoV-2 E (green circles), ORF1a (red squares) and ORF1b (blue triangles) gene copy numbers, expressed as RNA copies/μl of nucleic acid extract. Line and bars indicate median and interquartile range, respectively. **(B)** Correlation between Log₁₀SARS-CoV-2 E and ORF1a gene RNA copies/μl extract. **(C).** Correlation between Log₁₀SARS-CoV-2 E and ORF1b gene RNA copies/μl extract. **(D)** Correlation and Concordance between Log₁₀SARS-CoV-2 ORF1a and ORF1b gene RNA copies/μl extract.

$R^2 = 0.99901$

$\log_{10}$ SARS-CoV-2 E-gene RNA Copies Equivalent = $-0.3038(C_t) + 11.7$

Figure 6: Relationship between SARS-CoV-2 RNA copies equivalent and diagnostic test C_t value. C_t value, determined using the LightMix® 2019-nCoV real-time RT-PCR assay (E-gene target) is plotted against $\log_{10}$ SARS-CoV-2 E gene RNA copies equivalent, which represents the number of SARS-CoV-2 RNA copies measured by RT-ddPCR in 9 μ l extract (the template volume in the LightMix® assay). The linear regression (solid black line) transitions to a dashed line below the LLOQ.

Measured SARS-CoV-2 E gene RNA Copies/ Reaction

Supplementary Figure 1: All experiments using synthetic SARS-CoV-2 synthetic standards were performed in a consistent background of human nucleic acids to mimic a real human sample. Example experiment showing consistent levels of background human cells/ μ l extract (determined by dividing measured human RPP30 DNA copy number by two; black triangles), and human RNase P RNA levels (grey squares) across a titration of SARS-CoV-2 synthetic RNA standards, measured using the E-Sarbeco primer/probe set (green circles). Error bars indicate 95% Total Poisson Confidence Intervals for two merged replicates, where in some cases error bars are too small to visualize. Grey (RNase P) and black (RPP30) dashed lines indicate copies measured control experiments lacking SARS-CoV-2 RNA.

A **B**

Supplementary Figure 2: Duplexing the IP2 and IP4 primer/probe sets reduces analytical efficiency and precision. (A). Analytical efficiency of SARS-CoV-2 quantification was evaluated for the IP2 and IP4 primer/probe sets when used in separate reactions (dark red and dark blue, respectively) and when duplexed (light red and light blue, respectively), in reactions containing 1,000 and 100 viral RNA input copies. Error bars represent 95% Total Poisson Confidence Intervals. (B). Same as A, but for assay precision (coefficient of variation, CV%).

A **B**

Supplementary Figure 3: Log₁₀SARS-CoV-2 RNA loads in diagnostic specimens, normalized to human cells sampled. (A) SARS-CoV-2 E (green circles), ORF1a (red squares) and ORF1b (blue triangles) gene copy numbers, expressed as RNA copies/1,000 human cells. Line and bars indicate median and interquartile range, respectively. (B) Correlation between SARS-CoV-2 RNA copies/ μ l extract and RNA copies/1,000 human cells.

Supplemental Figure 4: Residuals of relationship between SARS-CoV-2 RNA copies equivalent and diagnostic test C_t value. $\text{Log}_{10}\text{Residuals}$ are calculated as $\text{log}_{10}\text{Measured SARS-CoV-2 RNA copies equivalent}$ minus $\text{log}_{10}\text{Calulated SARS-CoV-2 RNA copies equivalent}$ from the regression line shown in Figure 6.

$R^2 = 0.97079$

$\log_{10} \text{SARS-CoV-2 E-gene RNA Copies/1,000 Human Cells} = -0.3041(C_t) + 10.8$

Supplemental Figure 5: Relationship between SARS-CoV-2 RNA copies/1,000 human cells and C_t value. Same data as shown in Figure 6, but where the measured SARS-CoV-2 RNA copies/ μ l extract were normalized to copies/1,000 human cells. The linear regression is shown as a solid black line.